293 related articles for article (PubMed ID: 15886327)
61. FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.
Merlin S; Famà R; Borroni E; Zanolini D; Bruscaggin V; Zucchelli S; Follenzi A
Blood Adv; 2019 Mar; 3(5):825-838. PubMed ID: 30862611
[TBL] [Abstract][Full Text] [Related]
62. Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A.
Wang X; Shin SC; Chiang AF; Khan I; Pan D; Rawlings DJ; Miao CH
Mol Ther; 2015 Apr; 23(4):617-26. PubMed ID: 25655313
[TBL] [Abstract][Full Text] [Related]
63. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system.
Yakura Y; Ishihara C; Kurosaki H; Kazuki Y; Komatsu N; Okada Y; Doi T; Takeya H; Oshimura M
Biochem Biophys Res Commun; 2013 Feb; 431(2):336-41. PubMed ID: 23291180
[TBL] [Abstract][Full Text] [Related]
64. Factor VIII can be synthesized in hemophilia A mice liver by bone marrow progenitor cell-derived hepatocytes and sinusoidal endothelial cells.
Yadav N; Kanjirakkuzhiyil S; Ramakrishnan M; Das TK; Mukhopadhyay A
Stem Cells Dev; 2012 Jan; 21(1):110-20. PubMed ID: 21480781
[TBL] [Abstract][Full Text] [Related]
65. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
66. Correction of murine hemophilia A by hematopoietic stem cell gene therapy.
Moayeri M; Hawley TS; Hawley RG
Mol Ther; 2005 Dec; 12(6):1034-42. PubMed ID: 16226058
[TBL] [Abstract][Full Text] [Related]
67. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector.
Scallan CD; Lillicrap D; Jiang H; Qian X; Patarroyo-White SL; Parker AE; Liu T; Vargas J; Nagy D; Powell SK; Wright JF; Turner PV; Tinlin SJ; Webster SE; McClelland A; Couto LB
Blood; 2003 Sep; 102(6):2031-7. PubMed ID: 12738670
[TBL] [Abstract][Full Text] [Related]
68. Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII.
Chen H; Shi M; Gilam A; Zheng Q; Zhang Y; Afrikanova I; Li J; Gluzman Z; Jiang R; Kong LJ; Chen-Tsai RY
Sci Rep; 2019 Nov; 9(1):16838. PubMed ID: 31727959
[TBL] [Abstract][Full Text] [Related]
69. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats.
Van Damme A; Chuah MK; Dell'accio F; De Bari C; Luyten F; Collen D; VandenDriessche T
Haemophilia; 2003 Jan; 9(1):94-103. PubMed ID: 12558785
[TBL] [Abstract][Full Text] [Related]
70. Human, Pig, and Mouse Interferon-Induced Transmembrane Proteins Partially Restrict Pseudotyped Lentiviral Vectors.
Hornick AL; Li N; Oakland M; McCray PB; Sinn PL
Hum Gene Ther; 2016 May; 27(5):354-62. PubMed ID: 27004832
[TBL] [Abstract][Full Text] [Related]
71. Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A.
Saenko EL; Ananyeva NM; Moayeri M; Ramezani A; Hawley RG
Curr Gene Ther; 2003 Feb; 3(1):27-41. PubMed ID: 12553533
[TBL] [Abstract][Full Text] [Related]
72. Utilization of a novel Sendai virus vector in ex vivo gene therapy for hemophilia A.
Yamaki Y; Fukushima T; Yoshida N; Nishimura K; Fukuda A; Hisatake K; Aso M; Sakasai T; Kijima-Tanaka J; Miwa Y; Nakanishi M; Sumazaki R; Takada H
Int J Hematol; 2021 Apr; 113(4):493-499. PubMed ID: 33385293
[TBL] [Abstract][Full Text] [Related]
73. Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice.
Kren BT; Unger GM; Sjeklocha L; Trossen AA; Korman V; Diethelm-Okita BM; Reding MT; Steer CJ
J Clin Invest; 2009 Jul; 119(7):2086-99. PubMed ID: 19509468
[TBL] [Abstract][Full Text] [Related]
74. Next generation FIX muteins with FVIII-independent activity for alternative treatment of hemophilia A.
Quade-Lyssy P; Abriss D; Milanov P; Ungerer C; Königs C; Seifried E; Schüttrumpf J
J Thromb Haemost; 2014 Nov; 12(11):1861-73. PubMed ID: 25224783
[TBL] [Abstract][Full Text] [Related]
75. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
[TBL] [Abstract][Full Text] [Related]
76. Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.
Zhu F; Liu Z; Miao J; Qu H; Chi X
Sci China Life Sci; 2012 Jun; 55(6):521-6. PubMed ID: 22744182
[TBL] [Abstract][Full Text] [Related]
77. The Immune Response to the fVIII Gene Therapy in Preclinical Models.
Patel SR; Lundgren TS; Spencer HT; Doering CB
Front Immunol; 2020; 11():494. PubMed ID: 32351497
[TBL] [Abstract][Full Text] [Related]
78. Short-term correction of factor VIII deficiency in a murine model of hemophilia A after delivery of adenovirus murine factor VIII in utero.
Lipshutz GS; Sarkar R; Flebbe-Rehwaldt L; Kazazian H; Gaensler KM
Proc Natl Acad Sci U S A; 1999 Nov; 96(23):13324-9. PubMed ID: 10557319
[TBL] [Abstract][Full Text] [Related]
79. Complete short-term correction of canine hemophilia A by in vivo gene therapy.
Connelly S; Mount J; Mauser A; Gardner JM; Kaleko M; McClelland A; Lothrop CD
Blood; 1996 Nov; 88(10):3846-53. PubMed ID: 8916949
[TBL] [Abstract][Full Text] [Related]
80. Bioengineering of coagulation factor VIII for improved secretion.
Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
